Abstract 408P
Background
Sarcomas are a heterogeneous group of uncommon malignancies that are rarely encountered in most general oncology clinics and most general oncologists have very little experience in dealing with them. The Asian Sarcoma Consortium (ASC) is an international study group of oncologists specializing in sarcomas. The group has decided to start a Sarcoma Preceptorship Program. Its goal is increased awareness of the multidisciplinary approach in sarcomas. Objective is to conduct a program evaluation using the first 2 levels of the Kirkpatrick Model, involving Level 1 – focusing on satisfaction surveys of the participants and Level 2 – focusing on amount of information gained through a pre-test and a post-test.
Methods
Activities included didactic lectures, multidisciplinary case discussions and a summative multidisciplinary case presentation at the conclusion. Evaluation was done using satisfaction survey forms and a pre- and post-test. Novartis did their own survey & results were included in analysis, but had no direct participation in conduct of program.
Results
31 persons mostly Oncologists from University/Government Hospitals participated. 50% were consultants. Satisfaction surveys were optimistic, with ASC forms showing high level of satisfaction for the time and scope. Satisfaction level was high when helpfulness of topics was considered. Faculty response showed similar trends. Ratings remained consistent when the Novartis evaluation data were included. Areas for improvement included time management, content, language barriers and inconsistencies in facilitation. Results from pre-test and post-test showed test scores lower in post-test. Coefficient of Test reliability showed that pre-test was highly reliable but not post-test, the causes included external factors like time allotment for the post-test and presence of distractions.
Conclusions
The program was successful in terms of participant and faculty satisfaction. Results were supported by Novartis data. Certain areas for improvement were identified and recommendations were made.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asian Sarcoma Consortium.
Funding
Asian Sarcoma Consortium Novartis Pharma.
Disclosure
F.Y. Gracieux Jr.: Honoraria (self), RTD Speaker: Roche Philippines; Honoraria (self), Conference Speaker, RTD Speaker: Novartis Philippines; Honoraria (self), Webinar Moderator; RTD Speaker: Boehringer Ingelheim; Honoraria (self), Conference Speaker: GSK Philippines; Honoraria (self), Conference Speaker: Beacon Bangladesh; Honoraria (self), Conference Speaker; RTD Speaker: Roche Malaysia; Honoraria (self), Conference Speaker: Roche Myanmar.
Resources from the same session
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract